About the Journal

Overview

Clinical & Experimental Immunology (CEI) is an authoritative, international and well-respected journal publishing high-quality and impactful research and review articles in the field of translational immunology. The journal is brought to you by the British Society for Immunology.

All primary research papers published in Clinical & Experimental Immunology are:

  • Relevant to human disease

  • Based (in part) on translational research

  • Underpinned by novel mechanistic insight

Journal metrics

Citation metrics
Clarivate
2025 Impact Factor 3.9
2025 5 Year Impact Factor 4.2
Immunology (Rank by Impact Factor) 78/183
2025 Journal Citation Indicator (JCI) 0.68
Immunology (Rank by Journal Citation Indicator) 90/183
2025 Cited Half-Life 13.3 years
2025 Immediacy Index 0.9
2025 Eigenfactor Score 0.00542
2025 Article Influence Score 1.097
Scopus
2025 CiteScore 7.5
Immunology And Allergy (Rank by CiteScore) 59/234
Immunology (Rank by CiteScore) 65/243
2025 Source Normalized Impact per Paper (SNIP) 1.004
Altmetric
2025 Total Altmetric Attention Score 104
Readership
2025 Full Text Usage 361,999
Peer Review and Production
2025 Median days from submission to first decision 8 days
2025 Median days from submission to final decision 8 days

Aims and scope

Since 1966, Clinical & Experimental Immunology has published research at the forefront of translational and clinical immunology. We remain committed to studies that have the potential to transform the understanding of the immunopathology of human disease and influence both preclinical and clinical practice.

We welcome original research that provides mechanistic insights, whether through novel experimental findings, careful confirmation of previously published results, or incremental advances that clarify and extend existing knowledge.

We support robust, reproducible science, including confirmation studies enriched with additional data, that plays a crucial role in building a reliable foundation for clinical translation. We are especially interested in manuscripts that:

  • Identify and dissect molecular, cellular, or systemic mechanisms in immune function and dysfunction.

  • Provide well-designed experimental models or clinical investigations that advance our understanding of disease pathways.

  • Offer incremental but meaningful advances that address gaps, resolve inconsistencies, or refine existing hypotheses.

  • Integrate mechanistic findings with translational implications for diagnostics, prognostics, or therapeutics.

The journal embraces a broad range of approaches, from the application of state-of-the-art technologies, such as next-generation sequencing, metagenomics, and high-dimensional phenotyping, to innovative experimental or clinical designs that elucidate the mechanisms underlying disease processes, therapeutic responses, or trial outcomes.

Journal articles are assessed by our dedicated Section Editors, and our shared editorial vision is to be a trusted venue for robust, reproducible, and mechanistically informative research, where both groundbreaking breakthroughs and careful, incremental progress are valued for their contribution to the foundation upon which clinical advances are built.

Manuscripts that do not fit into one of the sections described below will be assessed by our Editor-in-Chief. All papers with high relevance to translational immunology are welcome.

Clinical & Experimental Immunology is part of the British Society for Immunology family of journals, including our sibling journals Immunotherapy Advances and Discovery Immunology.

Journal Sections

Led by Editor-in-Chief Professor Claudia Mauri, University College London, UK, the journal has dedicated sections including:

Immunometabolism

Led by Lizzy Rosser, University College London, UK

  • Mechanistic insights into the metabolic and bioenergetic pathways regulating immune cell differentiation and function in health and diverse inflammatory contexts.

  • Studies investigating how systemic metabolic disorders, such as obesity, diabetes and cardiovascular disease, reshape immune responses.

  • Application of cutting-edge in vitro, in vivo and multi-omic approaches to advance the understanding of cellular, tissue and systemic immunometabolism.

  • Identification of metabolic biomarkers and therapeutic targets, including opportunities for drug repurposing, in immune-mediated diseases including strategies to improve vaccine responses.

  • Experimental and translational studies defining how metabolic factors shaped by environmental, dietary or microbial stimuli impact immune system function in health and diverse inflammatory contexts.

Autoimmunity

Hellesen (et al.) (https://doi.org/10.1111/cei.13207)

AutoimmunityLed by Angelo Manfredi of Università Vita-Salute San Raffaele, Milan

  • Insights into the mechanisms underlying the onset, remission and relapse of autoimmune diseases.

  • Studies that report new therapies and biomarkers that reflect relevant pathogenetic events.

  • Experimental autoimmune diseases as a tool to understand the complexity of human autoimmunity.

  • Identification of the characteristics that will inform our understanding of autoimmunity and eventually improve the nosology, stratification and patient care.

  • Figure Credit: Hellesen (et al.) (https://doi.org/10.1111/cei.13207)

Hellesen (et al.) (https://doi.org/10.1111/cei.13207)

Cancer Immunity

Cancer immunityLed by Tanja de Gruijl, VUmc Amsterdam, Netherlands

  • Studies on (neo)adjuvant immunotherapy strategies, including immune checkpoint blockade, adoptive cell transfer, vaccination, oncolytic virotherapy, adjuvants, bispecific targeting and immune modulation approaches.

  • Immune monitoring and profiling studies of tumour conditioned microenvironments or systemic immunity, and the identification of (immune) biomarkers/signatures with predictive or prognostic value.

  • Studies providing novel mechanistic insights into immune control or escape of tumours, including studies on immune suppression, immunotherapy resistance, the role of the microbiome, metabolism, and epigenetics.

Harjunpää (et al.) (https://doi.org/10.1111/cei.13407)

Immune-mediated Inflammatory Diseases

Immune-mediated Inflammatory DiseasesLed by Ciriaco Piccirillo of McGill University, Canada

  • Detailed characterisation of the immune environment in human inflamed tissue, underpinned by mechanistic insight.

  • Application of cutting-edge technologies to advance the understanding of inflammation, its causes and consequences.

  • In vitro or in situ investigation of the cross-talk of the immune system with non-hematopoietic cells or systems.

 

 

Wehmeyer (et al.) (https://doi.org/10.1111/cei.12979)

Immunodeficiency

ImmunodeficiencyLed by Cindy Ma of the Garvan Institute of Medical Research, Australia

  • Insights into the mechanisms and causes of primary and secondary immunodeficiencies.

  • Identification of novel genetic defects, mutations or external factors which cause immunodeficiencies.

  • New insights into the molecular or cellular basis of immunodeficiency-related syndromes.

  • Application of new technologies to advance the understanding and treatment of immunodeficiency-related syndromes.

  • The use of novel therapeutics to treat immunodeficiencies.

Kienzler (et al.) (https://doi.org/10.1111/cei.12947)

Infectious Diseases and Vaccines

Infectious Diseases and VaccinesLed by Danny Douek, National Institute of Allergy and Infectious Diseases/National Institutes of Health/DHHS, USA, and Xiao-Ning Xu, Imperial College London, UK

  • Studies of vaccines in humans or preclinical animal models with a short time frame for translation into humans.

  • Biomarkers that correlate with clinical outcome in infectious diseases.

  • Host/pathogen relationships including host genetic determinants of susceptibility to infections.

  • Emerging infectious diseases.

  • Studies on the microbiome, therapeutic microbial manipulation, and anti-microbial resistance.

Williamson (et al.) (https://doi.org/10.1111/cei.13284)

Neuroimmunology

NeuroimmunologyLed by Sandra Amor, VUmc Amsterdam, Netherlands

  • Human or model systems that provide insights into the pathogenesis of immune-mediated diseases of the central and peripheral nervous systems.

  • Cellular/molecular studies that expand the understanding of neuroimmune diseases.

  • Proof-of-concept studies and preclinical trials of novel therapeutic approaches for neuroimmune diseases.

  • Biomarkers that correlate with clinical outcome in neuroimmune diseases.

  • Cutting-edge technologies to image neuroinflammation and aid the understanding of disease.

Bennett (et al.) (https://doi.org/10.1111/cei.13334)

Clinical & Experimental Immunology is also interested in articles in the following subject areas. These articles will be handled by one of our Section Editors.

Allergy, Asthma and Respiratory Immunology

Areas of interest include:Allergy, Asthma, and Respiratory Immunology

  • Studies that provide immunological insight into the development, treatment or diagnosis of respiratory disease or allergy.

  • Translational or clinical studies that report on immunological responses to respiratory diseases or allergies.

  • Technologies or models that advance the immunological understanding of respiratory disease, asthma, and allergy.

  • Investigations into infections that affect the respiratory system, including but not limited to SARS-CoV-2.

Boe (et al.) (https://doi.org/10.1111/cei.12881)

Immunity and Ageing

Areas of interest include: Immunity and Ageing

  • Studies describing age-related changes in immunity, as well as the testing of interventions to reverse these changes.

  • Molecular mechanisms underlying age-related immune dysfunction.

  • New strategies and technologies to counteract the age-related changes in immune response to disease and infection.

 

Nasi (et al.) (https://doi.org/10.1111/cei.12814)

 

 

The journal is also interested in articles covering all other areas of clinical and translational immunology, including; transplantation, immune regulation & recognition, immunometabolism, innate immunity and mucosal immunology.

In addition to primary research, Clinical & Experimental Immunology publishes highly-cited review articles. These are usually commissioned and published as review series, but suggestions to the Editor-in-Chief of topics for such series or titles for one-off review articles are welcome.

If you would like to submit an article to Clinical & Experimental Immunology, please visit our submission site page.

Abstracting and Indexing Information

  • Abstracts in Anthropology (Sage)

  • Abstracts on Hygiene & Communicable Diseases (CABI)

  • Academic Search (EBSCO Publishing)

  • Academic Search Alumni Edition (EBSCO Publishing)

  • Academic Search Elite (EBSCO Publishing)

  • Academic Search Premier (EBSCO Publishing)

  • AGRICOLA Database (National Agricultural Library)

  • Agricultural & Environmental Science Database (ProQuest)

  • BIOBASE: Current Awareness in Biological Sciences (Elsevier)

  • Biological Abstracts (Clarivate Analytics)

  • Biological Science Database (ProQuest)

  • BIOSIS Previews (Clarivate Analytics)

  • CAB Abstracts® (CABI)

  • CAS: Chemical Abstracts Service (ACS)

  • Current Contents: Clinical Medicine (Clarivate Analytics)

  • Embase (Elsevier)

  • Health Source Nursing/Academic (EBSCO Publishing)

  • HEED: Health Economic Evaluations Database (Wiley-Blackwell)

  • Journal Citation Reports/Science Edition (Clarivate Analytics)

  • MEDLINE/PubMed (NLM)

  • Natural Science Collection (ProQuest)

  • Proquest Pharma Collection (ProQuest)

  • PubMed Dietary Supplement Subset (NLM)

  • PubMed via PMC deposit (NLM)

  • Science Citation Index (Clarivate Analytics)

  • Science Citation Index Expanded (Clarivate Analytics)

  • SciTech Premium Collection (ProQuest)

  • VINITI (All-Russian Institute of Science & Technological Information)

Disclaimer

Statements of fact and opinion in the articles in Clinical & Experimental Immunology are those of the respective authors and contributors and not of the Journal, British Society of Immunology, or Oxford University Press, unless otherwise expressly indicated. Neither Oxford University Press, British Society of Immunology, nor the Journal make any representation, express or implied, in respect of the accuracy of the material in the Journal and cannot accept any legal responsibility or liability for any errors or omissions that may be made. Readers should make their own evaluation as to the appropriateness or otherwise of the information included.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close

Gift article access

As a benefit of your subscription, you can share temporary access to restricted articles.

Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Please sign in to your personal account to gift article access.

Gift article access

Please create a link below to share with others. This will provide temporary access to this restricted article.

The link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Gift articles remaining: --

Gift article access

The link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Gift articles remaining: --

Gift article access

As a benefit of your subscription, you can share temporary access to restricted articles.

Each link will stop working after 30 days or 10 uses.

You have reached the limit of 10 links within a 30 day period